Search the Newsreel

Biomea Fusion Announces First Patient Dosed in OPAL Study

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese individuals without type 2 diabetes. The study aims to assess whether adding icovamenib can enhance …

Hariom Pipe net profit falls 26% YoY to ₹1,736 crore in Q1FY27

Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biomea Fusion Inc (BMEA), detailing analyst ratings and price targets. Seven analysts have given BMEA a "Buy" rating with a target price of $6.50, representing a significant upside. The report also includes past and projected EPS figures …

Zimmer Biomet reports strong second quarter financial results

Zimmer Biomet Holdings Inc. announced strong financial results for the second quarter of 2026, with net sales increasing by 4.8% to $2.177 billion and adjusted diluted earnings per share at $2.07. The company is raising its revenue and adjusted EPS guidance for the year …

Hariom Pipe Industries consolidated net profit declines 29.66% in the June 2026 quarter

Judge approves $3.75 million Lifecore investor settlement

A federal judge has granted final approval for a $3.75 million settlement in a securities class action lawsuit against Lifecore Biomedical Inc. Investors accused Lifecore of making false statements about its financial condition and internal accounting controls, which led to a stock price drop …

Hariom Pipe Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. …

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Manager of Investor Relations - Stephanie Diaz President and Chief Executive Officer - Paul Josephs Chief Financial Officer - Ryan Lake Full Conference Call Transcript Operator: Good morning, …

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a …

Zimmer Biomet (ZBH): Capital International Investors reports 6.4% ownership stake

Capital International Investors has reported a 6.4% ownership stake in Zimmer Biomet Holdings, Inc. (ZBH), totaling 12,438,366 shares. This passive investment grants them sole voting power over 12,279,364 shares and sole dispositive power over all 12,438,366 shares, as detailed in a Schedule 13G SEC …

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion–$3.925 billion and non-GAAP EPS guidance to $4.90–$5.10. The Amicus acquisition added Galafold …

Zimmer Biomet (ZBH) Q2 2026 Earnings Call Transcript

Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA

Renaissance Technologies LLC significantly increased its stake in Biomea Fusion, Inc. (NASDAQ:BMEA) by 174.3% in the first quarter, now holding 1.31 million shares, representing 1.82% of the company. Institutional ownership of Biomea Fusion remains very high at 96.72%, with several other hedge funds also …

Assenagon Asset Management S.A. Buys 97,887 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Assenagon Asset Management S.A. significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, purchasing an additional 97,887 shares to bring its total holdings to 102,862 shares valued at $8.855 million. This comes as Zimmer Biomet reported strong quarterly earnings, …

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts

Analysts have given BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) an average "Moderate Buy" rating, with a consensus 12-month price target of $88.00. The company recently reported strong quarterly results, with revenue up 20% year-over-year and raised its 2026 VOXZOGO revenue guidance to at least $1 billion. …

Orchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Orchestra BioMed (NASDAQ:OBIO) reported a quarterly loss of $0.38 per share, missing analyst estimates by $0.03. Despite the earnings miss and negative financial metrics, the company's shares increased by 5.2% and insiders purchased a significant amount of stock. Analyst sentiment is mixed but generally …

Orchestra Biomed Holdings earnings beat by $0.01, revenue fell short of estimates

Orchestra Biomed Holdings (NASDAQ: OBIO) reported second-quarter EPS of $-0.380

Advanced Biomed Inc (ADVB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Advanced Biomed Inc (ADVB), covering future EPS, revenue, net profit, and EBIT growth estimates. It lists current stock performance metrics and offers a peer comparison with other healthcare companies like CVS Health Corp and HCA Healthcare Inc. …

Ping An Biomedical Ord Shs (PASW) Earnings Forecast: Future EPS & Revenue Growth Estimates

HARIOMPIPE Share Price Today - Hariom Pipe Industries Stock Analysis

Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.33, Implies 177% Upside

The average 12-month price target for Orchestra BioMed Holdings, Inc. (OBIO) stock has increased to $12.33, up from $12.17, according to estimates from six analysts. This new target suggests a potential upside of approximately 177% from its closing price on August 10. The consensus …

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day

Zimmer Biomet Holdings Inc. (ZBH) saw its stock advance by 1.27% to $97.78 on Monday, outperforming the broader market which experienced a dismal trading session. This rise broke a two-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial …

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed announced its second-quarter 2026 financial results, highlighting progress in its two cardiovascular programs: AVIM Therapy and Virtue SAB. The company reported that its BACKBEAT trial for AVIM Therapy is on track to meet its target enrollment by Q3 2026, with primary data …

Orchestra BioMed reports $24.1M Q2 loss, secures $35M capital

Orchestra BioMed Holdings reported a net loss of $24.1 million in Q2 2026, widening from the previous year, despite an 89% drop in revenue to $88,000. The loss was primarily due to increased research and development expenses for pivotal clinical trials. However, the company …

BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History

Orchestra BioMed Reports Q2 2026 Results and Updates Progress on BACKBEAT and Virtue Pivotal Trials

Orchestra BioMed reported its Q2 2026 financial results, including a net loss of $24.1 million, and provided updates on its pivotal clinical trials. The BACKBEAT Trial for uncontrolled hypertension is on track to enroll 284 patients by Q3 2026, with primary results expected in …

Orchestra BioMed (NASDAQ: OBIO) widens H1 2026 loss amid heavy R&D spend

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.35 loss, though it was an improvement from a $0.5 loss a year ago. The company also missed revenue estimates, posting $0.09 million against …

Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD

BioMarin Pharmaceutical (BMRN) stock reached a new 52-week high of $66.28, reflecting a 16.44% increase over the past year. InvestingPro analysis suggests the stock is undervalued with strong fundamentals, including 11.2% revenue growth. The company also reported impressive Q2 2026 results, exceeding Wall Street …

BioMarin Pharmaceutical Aktie erreicht 52-Wochen-Hoch bei 66,28 USD

RBC cuts Oxford BioMedica target by a fifth but sticks with 'buy' call

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation …

BioMarin presentation to stream live from Boston on Aug. 12

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 AM ET in Boston. A live audio webcast and a limited-time archived replay will be available on the company's investor …

Canaccord raises BioMarin stock price target on revenue growth

Canaccord has increased its price target for BioMarin Pharmaceutical Inc. (BMRN) to $114 from $111, maintaining a Buy rating, following strong second-quarter 2026 earnings. The company's revenue growth was significantly boosted by the acquisition of GALAFOLD and POMBILITI + OPFOLDA, leading to raised fiscal …

Zimmer Biomet (NYSE:ZBH) Price Target Raised to $100.00

Canaccord Genuity raised Zimmer Biomet's (NYSE:ZBH) price target from $83.00 to $100.00 while maintaining a "hold" rating, suggesting a 3.59% upside. The medical equipment provider recently reported strong quarterly earnings, beating EPS estimates by $0.06 and achieving a 4.8% year-over-year revenue increase. Analysts, on …